Avrobio Stock Up 16% on Positive Data for Cystinosis Treatment
18 5월 2023 - 9:14PM
Dow Jones News
By Sabela Ojea
Shares of Avrobio on Thursday climbed 16% to 67 cents in
pre-market trading Thursday after the company provided positive
data from its phase 1/2 clinical trial evaluating a cystinosis gene
therapy treatment.
The Cambridge, Mass.-based clinical-stage gene therapy company
said the cystinosis program has also received positive regulatory
feedback in meetings with the U.S. Food and Drug Administration and
U.K. Medicines and Healthcare products Regulatory Agency.
"We are excited about moving this investigational gene therapy
closer to patients," said Chief Medical Officer Essra Ridha.
Cystinosis is a rare genetic disorder characterized by the
accumulation of an amino acid in different tissues and organs of
the body.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 18, 2023 07:59 ET (11:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AVROBIO (NASDAQ:AVRO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
AVROBIO (NASDAQ:AVRO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
